Table 6.
Cause of death*,† while on sorafenib therapy or within 30 days of discontinuing therapy, by Child-Pugh status at study entry
| Deaths,n(%) | Total‡(n = 343) | Child-Pugh status | ||
|---|---|---|---|---|
| A§(< 7) (n = 154) | B§(7–9) (n = 125) | C (> 9) (n = 13) | ||
| HCC-related | 138 (40) | 61 (40) | 50 (40) | 4 (31) |
| HCC- and liver-related | 38 (11) | 15 (10) | 15 (12) | 3 (23) |
| HCC- and liver-related and MOF | 9 (3) | 4 (3) | 2 (2) | 1 (8) |
| Liver-related | 49 (14) | 22 (14) | 18 (14) | 2 (15) |
| HCC-related and MOF | 15 (4) | 8 (5) | 4 (3) | 0 |
| MOF | 22 (6) | 10 (7) | 8 (6) | 1 (8) |
HCC, hepatocellular carcinoma; MOF, multi-organ system failure.
*
Incidence > 2% in total population.
†
Patients may be included in more than one cause of death category.
‡
Child-Pugh status missing for one patient.
§
Data missing for seven Child-Pugh A and seven Child-Pugh B patients.